Tradestie Institutional Equity Comparison Engine
OBIO vs PYPD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PYPD Overall Edge
PYPD Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to PolyPid Ltd. Ordinary Shares (PYPD) driven by superior Growth & Margin, Momentum & Technical while OBIO counters with relative strength in Options & Structure. Fundamentally, OBIO trades at N/M Forward P/E with -195.4% operating margin (-89.4% YoY revenue) versus PYPD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro) against PYPD sits in BREAKOUT (12th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
OBIO N/M vs PYPD N/M Fwd P/E
Growth & Margin Winner
PYPD
Op Margin -195.4% vs 0.0% ยท YoY -89.4% vs +0.0%
Momentum & Technical Winner
PYPD
1Y +78.2% vs +81.0% ยท 52W Pos 89% vs 82%
Options & Structure Winner
OBIO
BREAKOUT (<1st %ile IV) vs BREAKOUT (12th %ile IV)
OBIO
NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.02
-1.4% 1D
Market Cap
$570.6M
1M Return
+24.25%
1Y Return
+78.17%
Forward P/E
N/M
Unified AI Score
42.9 / 100
HOLD
Tech 15.0
Fund 40.0
Flow 62.0
Mom 44.0
PYPD
NASDAQ
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.50
+5.63% 1D
Market Cap
$132.2M
1M Return
+33.12%
1Y Return
+80.95%
Forward P/E
N/M
Unified AI Score
31.1 / 100
SELL
Tech 50.0
Fund 27.0
Flow 56.0
Mom 32.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
OBIO +78.17%
PYPD +80.95%
Spread: +2.78 pp (PYPD Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
OBIO TTM Op. Margin: -195.4%
PYPD TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OBIO vs PYPD. Trailing 12-month operating profitability (OBIO -195.4% vs PYPD 0.0%) and valuation multiples (OBIO N/M vs PYPD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | OBIO | PYPD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $570.6M | $132.2M | Larger Scale | OBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -89.4% | +0.0% | Higher Growth | PYPD |
| Operating Margin (TTM) Profitability | -195.4% | 0.0% | Higher Margin | PYPD |
| Net Profit Margin Profitability | -182.5% | 0.0% | Higher Margin | PYPD |
| Return on Equity (ROE) Capital Efficiency | -182.3% | -243.6% | Higher ROE | OBIO |
| 52-Week Range Position Momentum | 89% ($3โ$7) | 82% ($4โ$7) | Stronger Trend | OBIO |
| Beta / 30D Volatility Risk Regime | 1.15ฮฒ ยท 80% Vol | 0.88ฮฒ ยท 59% Vol | Lower Realized Risk | PYPD |
| Unified Institutional Score Composite Signal | 42.9 / 100 (HOLD) | 31.1 / 100 (SELL) | Higher Composite | OBIO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full OBIO vs PYPD Buy Guide
OBIO
BREAKOUT
33d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
PYPD
BREAKOUT
40d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
12th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither OBIO nor PYPD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.